These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29497895)

  • 1. Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.
    Haney SL; Chhonker YS; Varney ML; Talmon G; Murry DJ; Holstein SA
    Invest New Drugs; 2018 Oct; 36(5):810-818. PubMed ID: 29497895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.
    Haney SL; Chhonker YS; Varney ML; Talmon G; Smith LM; Murry DJ; Holstein SA
    J Pharmacol Exp Ther; 2019 Nov; 371(2):327-338. PubMed ID: 31420526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
    Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
    Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
    Haney SL; Wills VS; Wiemer DF; Holstein SA
    Molecules; 2017 May; 22(6):. PubMed ID: 28555000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.
    Bhuiyan NH; Varney ML; Bhattacharya DS; Payne WM; Mohs AM; Holstein SA; Wiemer DF
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126633. PubMed ID: 31474482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma.
    Haney SL; Varney ML; Chhonker YS; Shin S; Mehla K; Crawford AJ; Smith HJ; Smith LM; Murry DJ; Hollingsworth MA; Holstein SA
    Oncogene; 2019 Jun; 38(26):5308-5320. PubMed ID: 30918331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
    Wasko BM; Dudakovic A; Hohl RJ
    J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application.
    Chhonker YS; Haney SL; Matthiesen RA; Wiemer DF; Holstein SA; Murry DJ
    J Pharm Biomed Anal; 2018 May; 153():22-28. PubMed ID: 29455093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.
    Wills VS; Metzger JI; Allen C; Varney ML; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2017 Apr; 25(8):2437-2444. PubMed ID: 28302510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.
    Allen C; Kortagere S; Tong H; Matthiesen RA; Metzger JI; Wiemer DF; Holstein SA
    Mol Pharmacol; 2017 Mar; 91(3):229-236. PubMed ID: 28057800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
    Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma.
    Haney SL; Feng D; Chhonker YS; Varney ML; Williams JT; Smith LM; Ford JB; Murry DJ; Holstein SA
    Drug Dev Res; 2023 Feb; 84(1):62-74. PubMed ID: 36433690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
    Matthiesen RA; Varney ML; Xu PC; Rier AS; Wiemer DF; Holstein SA
    Bioorg Med Chem; 2018 Jan; 26(2):376-385. PubMed ID: 29248353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
    Wiemer AJ; Wiemer DF; Hohl RJ
    Clin Pharmacol Ther; 2011 Dec; 90(6):804-12. PubMed ID: 22048229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.
    Muehlebach ME; Holstein SA
    Clin Transl Med; 2023 Jan; 13(1):e1167. PubMed ID: 36650113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new motif for inhibitors of geranylgeranyl diphosphate synthase.
    Foust BJ; Allen C; Holstein SA; Wiemer DF
    Bioorg Med Chem; 2016 Aug; 24(16):3734-41. PubMed ID: 27338660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
    Dykstra KM; Allen C; Born EJ; Tong H; Holstein SA
    Oncotarget; 2015 Dec; 6(39):41535-49. PubMed ID: 26595805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.
    Reilly JE; Zhou X; Tong H; Kuder CH; Wiemer DF; Hohl RJ
    Biochem Pharmacol; 2015 Jul; 96(2):83-92. PubMed ID: 25952057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Amino bisphosphonate triazoles serve as GGDPS inhibitors.
    Gehrke NR; Feng D; Ayub Ali M; Maalouf MA; Holstein SA; Wiemer DF
    Bioorg Med Chem Lett; 2024 Apr; 102():129659. PubMed ID: 38373465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
    Pham AC; Holstein SA; Borgstahl GEO
    Mol Cancer Ther; 2024 Jan; 23(1):14-23. PubMed ID: 37756579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.